Search Results

Gliquidone 200 mg  | Purity Not Available

TargetMol

Gliquidone is a potent, second-generation sulfonylurea with antihyperglycemic activity. Like other second-generation compounds, gliquidone exerts greater binding affinity to SUR1 and increased potency compared to first-generation compounds. In addition, this agent exerts peroxisome proliferator-activated receptor (PPAR) gamma agonistic activity.

More Information Supplier Page

Lafutidine 100 mg  | Purity Not Available

TargetMol

Lafutidine is a newly developed histamine H(2)-receptor antagonist, which can inhibit gastric acid secretion.

More Information Supplier Page

Lafutidine 25 mg  | Purity Not Available

TargetMol

Lafutidine is a newly developed histamine H(2)-receptor antagonist, which can inhibit gastric acid secretion.

More Information Supplier Page

Fluphenazine dihydrochloride 200 mg  | 100.00%

TargetMol

Fluphenazine dihydrochloride (Prolixin) is an inhibitor of phenothiazine-class D1DR and D2DR; In studies, Fluphenazine can be used to probe the effects and metabolic process of this commonly used dopamine antagonist.

More Information Supplier Page

Bupivacaine hydrochloride 200 mg  | Purity Not Available

TargetMol

Bupivacaine Hydrochloride is a long-acting, amide-type local anesthetic. Bupivacaine reversibly binds to specific sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions and membrane stabilization; inhibition of depolarization and nerve impulse conduction; and a reversible loss of sensation.

More Information Supplier Page

Sulfalene 200 mg  | Purity Not Available

TargetMol

Sulfalene, a long-acting sulfonamide antibiotic, is used for the therapy of chronic bronchitis, urinary tract infections, and malaria.

More Information Supplier Page

Entecavir 25 mg  | 99.72%

TargetMol

Entecavir is a guanosine nucleoside analogue used in the treatment of chronic hepatitis B virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis B during or after therapy, but has not been linked to cases of clinically apparent liver injury.

More Information Supplier Page